Increase in proportion of patients free from disease activity following 1 year of treatment with daclizumab high-yield process in relapsing-remitting multiple sclerosis: results from the SELECT study

被引：0
|
作者：
Giovannoni, G.
Stefoski, D.
Umans, K.
Greenberg, S.
Glyman, S.
Elkins, J.
机构：
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England
[2] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[3] Biogen Idec Inc, Cambridge, MA USA
[4] Abbott Biotherapeut, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：419 / 419
页数：1
相关论文
共 50 条
  • [1] Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study
    Havrdova, Eva
    Giovannoni, Gavin
    Stefoski, Dusan
    Umans, Kimberly
    Greenberg, Steven
    Mehta, Lahar
    Elkins, Jacob
    [J]. NEUROLOGY, 2013, 80
  • [2] Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study
    Havrdova, Eva
    Giovannoni, Gavin
    Stefoski, Dusan
    Forster, Samantha
    Umans, Kimberly
    Mehta, Lahar
    Greenberg, Steven
    Elkins, Jacob
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (04) : 464 - 470
  • [3] Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis
    Preiningerova, Jana Lizrova
    Vachova, Marta
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (01) : 67 - 75
  • [4] Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
    Gavin Giovannoni
    Ernst-Wilhelm Radue
    Eva Havrdova
    Katherine Riester
    Steven Greenberg
    Lahar Mehta
    Jacob Elkins
    [J]. Journal of Neurology, 2014, 261 : 316 - 323
  • [5] Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
    Giovannoni, Gavin
    Radue, Ernst-Wilhelm
    Havrdova, Eva
    Riester, Katherine
    Greenberg, Steven
    Mehta, Lahar
    Elkins, Jacob
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 (02) : 316 - 323
  • [6] Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extension study
    Giovannoni, G.
    Gold, R.
    Selmaj, K.
    Havrdova, E.
    Montalban, X.
    Radue, E. -W.
    Stefoski, D.
    McNeill, M.
    Rana, J.
    Elkins, J.
    O'Neill, G.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S50 - S51
  • [7] Efficacy of Daclizumab HYP Treatment in Patients with Highly Active Relapsing-Remitting Multiple Sclerosis: Results from the SELECT Study
    Mehta, Lahar
    Giovannoni, Gavin
    Radue, Ernst-Wilhelm
    Havrdova, Eva
    Riester, Katherine
    Greenberg, Steven
    Elkins, Jacob
    [J]. NEUROLOGY, 2013, 80
  • [8] Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study
    Giovannoni, G.
    Radue, E. W.
    Havrdova, E.
    Riester, K.
    Greenberg, S.
    Glyman, S.
    Elkins, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 189 - 189
  • [9] Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
    Tran, Jonathan Q.
    Othman, Ahmed A.
    Mikulskis, Alvydas
    Wolstencroft, Paul
    Elkins, Jacob
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 : 9 - 13
  • [10] Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
    Gold, Ralf
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Radue, Ernst-Wilhelm
    Stefoski, Dusan
    Robinson, Randy
    Riester, Katherine
    Rana, Jitesh
    Elkins, Jacob
    O'Neill, Gilmore
    [J]. LANCET, 2013, 381 (9884): : 2167 - 2175
12345